In clinical trials, both cholinesterase inhibitors and memantine have proven beneficial to AD patients. However, these drugs only show modest effects on AD patients’ cognitive test scores, behavioral measures, and functional outcomes. In this review, we describe some recent interesting findings that point to new concepts about AD.